12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Thu, 09 Oct 2025 07:47:24 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Cache-Control: no-cache, private [5] => Cache-Control: no-cache, no-store, must-revalidate [6] => Nel: {"report_to":"cf-nel","success_fraction":0.0,"max_age":604800} [7] => x-frame-options: SAMEORIGIN [8] => x-content-type-options: nosniff [9] => x-xss-protection: 1; mode=block [10] => referrer-policy: strict-origin-when-cross-origin [11] => permissions-policy: geolocation=(), microphone=(), camera=() [12] => content-security-policy: default-src * 'unsafe-inline' 'unsafe-eval' data: blob:; script-src * 'unsafe-inline' 'unsafe-eval' data: blob:; style-src * 'unsafe-inline' data:; img-src * data: blob:; font-src * data:; connect-src *; frame-src *; object-src *; media-src *; child-src *; [13] => Server: cloudflare [14] => x-robots-tag: noindex, nofollow, nosnippet, noarchive [15] => strict-transport-security: max-age=31536000; includeSubDomains; preload [16] => expires: Fri, 10 Oct 2025 07:47:24 GMT [17] => vary: Accept-Encoding [18] => Report-To: {"group":"cf-nel","max_age":604800,"endpoints":[{"url":"https://a.nel.cloudflare.com/report/v4?s=K3BpK%2FRu6IPCwu3lKlvmSKMUAunDNWaRMvkPCEVyxOFiFUUUaBK12nP6UcsFIzQuSIc4c4jiR%2Bmu70oD72ewKBQBEd6tugexbzOuIFY%3D"}]} [19] => cf-cache-status: DYNAMIC [20] => Speculation-Rules: "/cdn-cgi/speculation" [21] => Server-Timing: cfCacheStatus;desc="DYNAMIC" [22] => Server-Timing: cfEdge;dur=2,cfOrigin;dur=89 [23] => Set-Cookie: UpalLiveSession=eyJpdiI6IkxoT3FJcEF4ck16aFBUYWY0N1BmRmc9PSIsInZhbHVlIjoia2c4eVRaSW1kMVhuem53cXR3YmFwc0trRnVYbEVzZ0xmNG9VZ1VlXC9BaG5LSVwvTkdWSTVvdFwvTXloYlwvdWNJQWRFaldXNTQ2Wk0xZmZXRDRCMkdwUXFBPT0iLCJtYWMiOiJhOThlMDMxNDEzZjg5MDk1MTZhZWJhZWJlMmE1MGZmYzExN2FjNzVjOWJmNmVjNjgwNDVmOGJlZGJhNjU3OWYzIn0%3D; HttpOnly; Path=/; Max-Age=94608000; Expires=Sun, 08 Oct 2028 07:47:24 GMT [24] => CF-RAY: 98bc450c0d4335be-KUL [25] => alt-svc: h3=":443"; ma=86400 ) 789

美国吉利德科学公司研发的药物“瑞德西韦”，被认为可望抑制新型冠状病毒感染，中国科学家于周三已在武汉启动临床试验，用于治疗新冠肺炎患者。

媒体报导，主导瑞德西韦研发工作的是来自台湾的女科学家，也就是吉利德制药部门执行副总裁杨台莹。

根据吉利德网站介绍，杨台莹毕业于台湾大学化学系，也拥有南加州大学有机化学博士学位。

她领导吉利德的药物研发与制造部门，负责该公司研发与上市产品。在她的领导下，吉利德研发出全球第一款治疗HIV单锭药物，也将多于25种复方制剂研发成药品。

北京“中日友好医院”的王辰、曹彬团队于周三下午在武汉市金银潭医院宣布启动瑞德西韦治疗2019新型冠状病毒感染临床3期研究，首批试验761位患者。